BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Jeffrey V. Matous,[1] Hui-Peng Lee,[2] Stephen S. Opat,[3] John Hrom,[4] David Kliman,[5] Paula Marlton,[6] Peng Liu,[7] Chenmu Du,[8] Amber Lussier,[9] Jun Zhang,[9] Haiyi Guo,[10] Steven P. Treon[11]

[1]Colorado Blood Cancer Institute, Denver, CO, USA; [2]Flinders Medical Centre, Bedford Park, SA, Australia; [3]Lymphoma Research Group, School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; [4]Hattiesburg Clinic, Hattiesburg, MS, USA; [5]GenesisCare North Shore, St Leonards, NSW, Australia; [6]Princess Alexandra Hospital and University of Queensland, Brisbane, QLD, Australia; [7]Affiliated Zhongshan Hospital of Fudan University, Shanghai, China; [8]BeiGene (Beijing) Co, Ltd, Beijing, China; [9]BeiGene USA, Inc, San Mateo, CA, USA; [10]BeiGene (Shanghai) Co, Ltd, Shanghai, China; [11]Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

Presented at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12); October 17-19, 2024; Prague, Czech Republic
Data originally presented at the 2024 ASCO Annual Meeting; May 31-June 4, 2024; Chicago, IL, USA. Abstract TPS7090

Disclosures for Jeffrey V. Matous

- Consulting or advisory role: BeiGene

Introduction

- WM is a rare, incurable, B-cell malignancy for which BTK inhibitors and anti-CD20 antibody–based therapies are preferred treatment options[1]
  - To date, no treatments have been approved for patients with WM that is refractory to both BTK inhibitors and anti-CD20 antibody–based therapy
- Venetoclax, the first-generation BCL2 inhibitor, has demonstrated clinical activity in patients with R/R WM but is not currently approved for WM[2]
- Sonrotoclax (BGB-11417), a next-generation BCL2 inhibitor, is more selective and a more pharmacologically potent inhibitor of BCL2 than venetoclax[3]
- In the ongoing phase 1 BGB-11417-101 (NCT04277637) study, sonrotoclax monotherapy has been well tolerated at doses up to 640 mg and has preliminary antitumor activity in patients with R/R WM[4]
- Based on these encouraging preclinical and clinical data, a phase 2 study of sonrotoclax monotherapy and sonrotoclax in combination with zanubrutinib in WM was designed and is currently enrolling globally

R/R, relapsed refractory; WM, Waldenström macroglobulinemia.

1. Castillo JJ, et al. *Lancet Haematol*. 2020;7(11):e827; 2. Castillo JJ, et al. *J Clin Oncol*. 2022;40(1):63-71; 3. Hu N, et al. AACR 2020; Abstract 3077;
4. Soumerai JD, et al. ASH 2022; Abstract 4201.

BGB-11417-203 (NCT05952037): An Open-Label, Multicenter, Phase 2 Study of Sonrotoclax ± Zanubrutinib in Patients With WM

Key Eligibility Criteria

- Aged ≥18 years
- Histologically-confirmed WM
- Adequate bone marrow and organ function
- ECOG PS of 0-2
- No prior BCL2 inhibitor
- No CNS involvement by WM
- No transformation to aggressive lymphoma



[a] To monitor and mitigate TLS risk, TLS prophylaxis and laboratory monitoring are used, and clinical visits are required on ramp-up days.
BTKi, BTK inhibitor; PI, proteasome inhibitor; R/R, relapsed/refractory; TLS, tumor lysis syndrome.

BGB-11417-203 Endpoints

Primary (Cohort 1)

- MRR[a] by IRC

Secondary (Cohorts 1-3)

- MRR by INV, by IRC (Cohorts 2 & 3 only)
- ORR and DOR by INV and IRC
- CR + VGPR rate and time to MR by INV and IRC
- PFS by IRC and INV
- OS
- Safety and tolerability
- HRQoL

Secondary (Cohort 4)

- MRR by INV
- ORR and DOR by INV
- CR + VGPR rate and time to MR by INV
- Time to next treatment
- Safety and tolerability
- HRQoL

[a] Proportion of patients achieving PR or better per IWWM-11 response criteria.
DOR, duration of response; HRQoL, health-related quality of life; INV, investigator; IRC, independent review committee; MRR, major response rate; ORR, objective response rate; VGPR, very good partial response.

BGB-11417-203 Study Status

- Enrollment for BGB-11417-203 began in September 2023, and the study is currently recruiting
- Approximately 72 study sites in Australia, China, Europe (Italy, Spain, France, Greece), the UK, Canada, and the US are planned





Acknowledgments

The authors would like to thank the investigators, site support staff, and especially the patients for participating in this study. This study was sponsored by BeiGene, Ltd. Medical writing support was provided by Shanen Perumal, PhD, of Nucleus Global, an Inizio company, and supported by BeiGene.